Patients with heart failure often require complex, coordinated treatment. This session will give you the tools to improve outcomes of your patients with heart failure through enhanced understanding and utilization of HF medications and other interventions, and better coordination of transitional care. 

Learning Objectives

  • Identify and mitigate barriers to providing optimal care for patients with heart failure
  • Utilize recommendations, that are based on efficacy and safety, to comanage patients with heart failure
  • Implement strategies to enhance the utilization of transitional care teams in order to improve patient-centered outcomes in heart failure 

Faculty Disclosures

James L. Januzzi Jr., MD, FACC, FESC

Advisory boards for Amgen; Boehringer Ingelheim Pharmaceuticals, Inc.; Critical Diagnostics; Koninklijke Philips N.V.; Novartis Pharmaceuticals Corporation; and Sphingo Tec GmbH. Research funding from Roche Diagnostics, North America; Prevencio; and Singulex, Inc. 


Paul J. Hauptman, MD, FHFSA

Speaker’s Bureau for Amgen Inc.; Otsuka America Pharmaceutical; Relypsa Inc. Advisory Board for Amgen Inc.; BioControl Medical, Relypsa Inc.; Sunshine-Medical; and St. Jude Medical Inc. Non CME/CE Services for Alnylam Pharmaceuticals Inc. 


Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Commercial Supporter

Amgen and Novartis Pharmaceuticals Corporation 

Education Partner

MedEd Consulting, Inc. 

Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.